Research field (1)：
Tumor diagnostics and therapeutics
Research keywords (7)：
Lung cancer
, Targeted therapy
, MET
, ALK
, EGFR
, ROS1
, KRAS
Research theme for competitive and other funds (4)：
2022 - 2026 Elucidation and Overcoming the Primary Resistance Mechanism in MET-driven Lung Cancer
2021 - 2023 Analysis of CBL gene mutations as a novel therapeutic target for lung cancer
2019 - 2021 Development of new treatment strategy for lung cancer haboring MET exon14 mutation
2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
Papers (134)：
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong-Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. 29. 16. 3004-3016
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of hematology & oncology. 2022. 15. 1. 79-79
Drugs for lung cancer that has acquired resistance to type I TKIs.
Books (4)：
Respiratory Medicine
2022
Respiratory Journal
2020
PROGRESS IN MEDCINE
lifescience 2018 ISBN:9784898016374
検診胸部X線写真の読影
国際医学出版 2016 ISBN:4861022630
Lectures and oral presentations (8)：
Preclinical Activity of NVL-655 in Patient-Derived Models of ALK Cancers, Including Those with Lorlatinib-Resistant G1202R/L1196M Compound Mutation
(EORTC-NCI-AACR 2022 2022)
Proposal of foretinib as second-line TKI after capmatinib/tepotinib treatment failure in NSCLC with MET exon14 mutation.
(IASLC 2022 World Conference on Lung Cancer 2022)
Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data
(2022 the Japanese Society of Medical Oncology Annual Meeting 2022)
Comprehensive analysis of secondary mutation as resistance mechanism to seven MET-TKIs for MET exon 14 skipping in vitro
(2019)
In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
(19th World Conference on Lung Cancer 2018)
2017 - 2020 Kindai University Faculty of Medicine Graduate School of Medical Sciences
2006 - 2012 Nagoya City University
Work history (5)：
2022/04 - 現在 Massachusetts General Hospital Cancer Center Research fellow
2017/04 - 2022/03 Kindai University Faculty of Medicine Thoracic Surgery
2017/01 - 2017/03 Nagoya City University Thoracic Surgery
2014/04 - 2016/12 Seirei Mikatahara General Hospital Thoracic Surgery
2012/04 - 2014/03 Ijinkai Takeda General Hospital
Awards (5)：
2022/04 - Takeda Science Foundation Research grant for Study Abroad
2020/11 - The Japan Lung Cancer Society Young Scientist Award
2020/07 - Kindai University Medical Society Award
2020/03 - Kindai University Kindai University President Award
2017/02 - 静岡呼吸器外科医会 最優秀演題賞
Association Membership(s) (10)：
The Japanese Respiratory Society
, IASLC
, ASCO
, THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY
, THE JAPAN LUNG CANCER SOCIETY
, THE JAPANESE ASSOCIATION FOR THORACIC SURGERY
, The Japanese Association for Chest Surgery
, JAPAN SURGICAL SOCIETY
, THE JAPANESE CANCER ASSOCIATION
, THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER
